These authors contributed equally to all experimental aspects of this work. Results: Most biomarkers were similarly expressed or lost in expression in most samples analyzed, and the matched primary and metastases from a specific patient were most similar to each other than to other patients. However, a subset of proteins showed extensive inter-patient heterogeneity one of which was p38 MAPK. Strong positive pp38 MAPK immunolabeling was significantly correlated with improved post-resection survival by multivariate analysis (median overall survival 27.9 months, p=0.041). In pancreatic cancer cells, inhibition of functional p38 by SB202190 increased cell proliferation in vitro in both low-serum and low-oxygen conditions. High functional p38 activity in vitro corresponded to lower levels of pJNK protein expression, and p38 inhibition resulted in increased pJNK and pMKK7 by Western blot. Moreover, JNK inhibition by SP600125 or MKK7 siRNA knockdown antagonized the effects of p38 inhibition by SB202190. In vivo, SP600125 significantly decreased growth rates of xenografts with high p38 activity compared to those without p38 expression.
INTRODUCTION
Despite substantial progress in our understanding of this disease, survival of patients with pancreatic ductal adenocarcinoma remains relatively unchanged over the past 3 decades. Most patients will die of their disease within 5 years. Surgical resection provides the best chance of long-term survival but recurrences occur in most and 5-year survival in this group is only in the range of 20%. The lack of effective population based screening methods, coupled with relatively few treatment options and late stage of diagnosis, all contribute to these statistics (1). Thus, studies to understand the molecular characteristics of pancreatic cancers that impact upon their biological behavior, treatment resistance and ultimately patient survival are needed. Such information would prove invaluable not only for guiding clinical management but for revealing cellular pathways of significance for this disease.
Well documented pathologic markers that correlate with survival in patients with pancreatic cancer include tumor size, level of differentiation and lymph node status (2) . Numerous molecular biomarkers for pancreatic cancer have also been described; these can be categorized into diagnostic markers such as Ca19-9, prognostic markers such as Smad4 or MUC1, and predictive markers such as SPARC, HuR or members of the BRCA2 family (3) . However, given the wide variety of biomarkers reported and the lack of available pancreatic cancer samples with high-quality outcome data, it remains difficult to stratify these biomarkers into those with the most promise for utility in the clinical setting. Thus, unbiased approaches provide optimal methods to stratify such markers into those most suitable for use in the clinical setting. For example, Winter et al used a survival based tissue microarray of resected pancreatic cancers in association with a set of stringent criteria to identify among more than 2000 potential biomarkers those that were most predictive of patient outcome. This approach identified MUC1 and mesothelin both of which were superior to pathologic features and other putative markers for predicting post operative survival >30 months (4) . Such a methodology also has value as it provides clues to the biologic features of pancreatic cancer that underlie the expression of these biomarkers. For example, MUC1 overexpression may enhance HIF-1α stabilization and hypoxia-driven angiogenesis, promote formation of a reactive tumor microenvironment that facilitates metastasis, and induce epithelial to mesenchymal transition (5) (6) (7) . By contrast, given that mesothelin-specific T-cell responses have been associated with longer survival of pancreatic cancer patients (8) , loss of expression of this molecule may signify escape of pancreatic cancer cells from immune surveillance (9) .
The goal of this study was to perform biomarker profiling to identify biologic pathways that influence patient survival following surgical resection. To accomplish this goal we used a two well-annotated sets of pancreatic cancer tissues from patients with known patterns of failure at autopsy and from patients who underwent a potentially curative resection (1). Such knowledge is critical for the ultimate goal of identifying the specific features of pancreatic cancer present in diagnostic materials that can be exploited for decision-making during clinical management. We now show that phosphop38 MAPK expression in pancreatic cancer tissues corresponds to a significant survival advantage in pancreatic cancer patients in the adjuvant setting, and that the mechanism by which functional p38 MAPK promotes survival is due to its ability to inhibit JNK activity at the cellular level. Immunolabeling and Scoring Strategy. Unstained 5-µm sections were cut from each TMA paraffin block and the slides were deparaffinized by routine techniques followed by incubation in 1× sodium citrate buffer (diluted from 10× heat-induced epitope retrieval buffer, Ventana-Bio Tek Solutions, Tucson, AZ) before steaming for 20 minutes at 80°C. Slides were cooled 5 minutes before incubation with each primary antibody (see Supplemental Table 2 for primary antibody details). Immunolabeling was detected per kit instructions (Ventana IVIEW Detection Kits, catalog 760091). Negative controls for each of the antibodies were performed using nonimmune serum instead of the primary antibody. Slides were scored by two of the authors at a two-headed microscope (Y.N. and C.I.D.). For each antibody, the intensity value (scale 0 to 3) and the percent positive cells were multiplied to generate a Histology Score (H-score) with H = % positive cells x intensity of labeling. Using this system H-scores ranged from 0 to 300.
H-scores were calculated for each core independently, and the average of all cores for a Hierarchical Cluster Analysis. Agglomorative hierarchical clustering based on Euclidean distance and using Ward's method with complete linkage was used to cluster H-score data over both genes and samples(11). Multivariate logistic regression was used to evaluate the predictive power of candidate biomarkers of metastatic burden. The response variable was metastatic burden with samples classified as low (MB≤10) or high (MB>10), and 12 markers found to have significant variation across samples were used as predictors. To mitigate the effects of overfitting, performance was evaluated with leave-one-out cross-validation. Specifically, each sample was set aside in turn, while the coefficients of the logistic regression model were estimated using the remaining samples. The resulting model was applied to the left out sample in order to predict the metastatic burden. Both continuous predictions (the estimated probability of high MB) and binary predictions (estimated probability of high MB >0.5) were In vitro Cell Proliferation. All tumor cell lines were cultured in DMEM supplemented with 10% FBS, 100 units/ml penicillin, 100 μg/ml streptomycin and 2 mmol/L Lglutamine at 37°C and 5% CO2. Cells were treated with p38 inhibitors (SB202190, SB203580 and SB239063) at a variety of concentrations (5 μM, 10 μM or 20 μM), or treated with p38 inhibitors and 10 μM of gemcitabine (GEM) then analyzed for cell proliferation at 1, 24, 48 and 72 hour points using cell counting Kit-8 (Dojindo molecular technologies, Kumamoto, Japan). As for JNK inhibitor treatment experiments, 10 μM of SP600125 was used. Each assay experiment was performed in triplicate and data was 
RESULTS
Biomarker Profiling of Pancreatic Cancer. A discovery set of 36 patients' pancreatic cancer tissues was used to create a tissue microarray for biomarker profiling ( Figure 1A ).
For 30 of these patients the two cores each of the primary carcinoma and one matched metastasis were included, and for six patients no metastatic disease was found at autopsy and thus four cores of the primary carcinoma were included. The clinicopathologic features of these patients are shown in Supplemental Table 1 .
Immunolabeling was performed on recuts of this TMA for 35 different proteins representing a variety of cellular pathways, desmoplastic stromal constituents or oncoproteins reported to play a role, either directly or indirectly, in pancreatic cancer biology ( Figure 1B and Supplemental Table 2 ). High quality labeling was achieved for 94% of the total 5184 cores analyzed, corresponding to a total of 4889 individual datapoints of immunolabeling data. For proteins such as β-catenin or Yes-associated protein (YAP), in which pattern of expression is important, both the intensity of labeling and the location of labeling were recorded. In order to identify expression patterns that represented similar biological behavior, the dataset was next analyzed by unsupervised hierarchical cluster analysis ( Figure 1C ). In general, the primary and metastases from a specific patient were most similar to each other than to other patients. A tendency to clump patients with similar metastatic burdens was also noted, although there were many such clusters that were all relatively small and interspersed with one another.
Boxplots where then created for each protein organized by primary versus metastasis, and by metastatic burden (Supplemental Figure 1) . This again showed little variation across primary versus metastatic site, and across categories of metastatic burden.
However, some proteins such as Smad4 did show a relationship with metastatic burden, consistent with prior reports for this gene product (12,13).
Closer review of the data indicated the presence of three clusters using this set of markers ( Figure 1C those with either frequent loss of expression (i.e. CDKN2A) or overexpression compared to normal ductal epithelium (i.e. Ca19-9) in the majority of cancer tissues studied. Such patterns are consistent with the general dysregulation of gene expression that accompanies pancreatic carcinogenesis (14) (15) (16) (17) . This cluster also included cytoskeletal and matrix proteins that were consistently negative in both normal and neoplastic samples (i.e. CK20). By contrast, Cluster 3 corresponded to those proteins with expression patterns that were similar in intensity or cellular localization to that of normal epithelial cells in the majority of these samples. These proteins included those such as CK7, a marker of pancreaticobiliary epithelium, and the transcription factor Gata6. Finally, Cluster 2 corresponded to tissue biomarkers with significant heterogeneity of expression across the samples and patients analyzed, and this cluster of proteins was further explored.
Identification of p38 MAPK as a Biomarker of Patient Outcome. Cluster 2
corresponded to 12 (33%) of the 35 proteins analyzed. These 12 proteins were highly meaningful for pancreatic cancer biology and included MUC5AC, cyclin D1, p53, p63, β-catenin, pp38, pJNK, pAKT, S100A2, YAP, EGFR and mesothelin. β-catenin and YAP alterations in this cluster corresponded specifically to their altered cellular localization (membranous and cytoplasmic, respectively) compared to the patterns expected for normal epithelial cells (18) .
To determine the potential relevance of this subset of markers, we first used a logistic regression model of these 12 proteins to predict met burden> 10, in a leave-oneout cross validation. This correctly predicted 30 of 40 pancreatic cancers as having high burden and 10 of 16 as having low burden, further suggesting the biologic significance of this set of proteins ( Figure 1D ). Next, we immunolabeled a validation set of 83 surgically resected pancreatic cancers for 11 of these proteins and correlated their expression patterns to patient outcome. Clinical features of these 83 patients are shown in Supplemental (19, 20) (Figure 1E and Supplemental Figures 2A, 2B ). Of interest, cytoplasmic phospho-p38 MAPK (pp38) overexpression within the neoplastic epithelium corresponded to an improved overall survival in these same patients (p=0.0155), with a median overall survival of 24.4 months (95% CI: 19.7-29.1 months) for carcinomas with high expression (H-score >150) compared to 14.7 months (95% CI: 7.6-21.8 months) for those with low expression (H-score ≤150)( Figure 1E and Supplemental Figure 2C ). High pp38 expression also corresponded to a higher likelihood of a lymph node ratio <0.4 (p=0.031) (Supplemental Table 4 ). There was no difference in the rates of pp38 overexpression in these 83 resected carcinomas (53 of 83, 64%) compared to that of the 36 patients with end stage disease in the discovery set of patients (28 of 36, 78%) (p=0.1345), suggesting loss of pp38 does not occur to a greater extent with disease progression.
Given that a subset of these patients did not complete adjuvant chemoradiation, a reflection of poor performance status or disease progression (21) , or details of adjuvant data were not available, we repeated the survival analysis of pp38 expression solely among the 41 patients confirmed to have completed adjuvant therapy. The vast majority of these patients received 1-2 cycles of gemcitabine followed by adjuvant 5-FU based chemotherapy and radiation to 50-54 Gy followed by another 2-4 months of gemcitabine as per the Radiation Therapy Oncology Group Trial (RTOG) 97-04 (22) .. Some patients received adjuvant therapy closer to home; while confirmed to have completed therapy the full details were not available. This analysis maintained a significant relationship between pp38 expression and overall survival, with patients with high expression having a median overall survival of 28.4 months (95% CI: 21.9-38.4 months) compared to those with low expression having a median overall survival of 15.0 months (95% CI: 9.3-20.6 months) (p=0.012), an almost two-fold difference ( Figure 1F ).
We further evaluated pp38 overexpression in a multivariate model in the 26 patients similarly treated per RTOG 97-04, indicating that pp38 overexpression was an independent predictor of improved patient survival in this cohort (Table 1 and Supplemental Figure 2D ).
Research. No relationships with overall survival were found for the remaining proteins; this does not rule out the significance of these proteins for pancreatic cancer biology, only that their expression patterns were not a reliable predictive marker of patient outcome in our validation set. Given that the role of p38 MAPK in pancreatic cancer outcome has not been explored in detail, we sought to determine the significance and mechanisms of action of this signaling pathway in pancreatic cancer.
Functional p38 acts by restraining pancreatic cancer cell growth. To determine the extent to which p38 is functionally expressed in pancreatic cancer, we performed western blotting for total and phosphorylated forms of p38α as this is the predominant isoform expressed in most cell types (23) in two immortalized normal and seven pancreatic cancer cell lines (Figure 2A ). Despite detectable total p38 protein in six of seven cancer cell lines, only three (Panc5.04, A10.7 and A38.44) expressed significant levels of phosphorylated p38 suggesting endogenous activation of the pathway in these cells. To confirm pp38 was functional, we determined the abundance of phospho-ATF2 in each cell line by western blot, a known protein target of pp38 (24) . Levels of pATF2 paralleled levels of pp38 protein, further indicating that this subset of pancreatic cancer cell lines has functional p38 expression.
To determine the general mechanism by which p38 functional activity may contribute to pancreatic cancer survival in patients, we used three different and as an additional confirmation these effects were specific to p38 activity, we repeated the cell proliferation assays in cell lines A2.1 and A6L that do not express high levels of pp38 (Figure 2A ). Modest decreases in growth were seen in these cell lines after addition of SB202190, consistent with off-target effects in these cells ( Figure 2E ).
Thus, we conclude that functional p38 expression in pancreatic cancer cells acts by restraining cell growth, consistent with data indicating p38 negatively regulates the cell cycle at the G1/S and G2M transitions (25) . Note that for A2.1 and A6L cells we considered the possibility that lack of functional p38 may reflect growth in culture conditions and not the microenvironment that these cells arose in. To address this possibility we immunolabeled the matched paraffin embedded tissues that these cell lines were originally derived from for pp38 expression. Weak or no expression was seen for pp38 ( Figure 2B ) indicating that their lack of pp38 expression in vitro is an accurate reflection of their in vivo status for this phosphoprotein.
Because p38 coordinates signals related to environmental and inflammatory stresses (1,23), we nonetheless repeated these assays in the setting of low serum and low oxygen conditions to mimic features of the microenvironment typical of human pancreatic cancer (2,26-28) (Supplemental Figure 4) . A physiologic response to hypoxia in all cells was confirmed by upregulation of the HIF-1α target genes ADM and NDRG-1 (Supplemental Figure 4B) (3, 29) . Growth of each cell line in 1% FBS or 1% O 2 ((Supplemental Figure 4A,4C ) for up to 96 hours led to a reduction in cell proliferation, whereas p38 inhibition in the setting of low serum or oxygen abolished this effect, indicating that functional p38 restrains cell growth in conditions of cellular stress typical of the pancreatic cancer microenvironment. 
DISCUSSION
In the future, comprehensive characterizations that merge clinical, pathologic and molecular data at the time of diagnosis of a pancreatic neoplasm will provide the greatest benefit to patients by allowing a personalization of their care (9, 33) . This study thus aims to fulfill that purpose by surveying a large series of biomarkers in a set of wellannotated discovery set of patient specimens. It is important to note that this biomarker list was not meant to be all inclusive but rather to consider major pathways and oncoproteins of significance for solid tumors including pancreatic cancer, a list that continues to grow (1,3). Our sample set is also not fully representative of all patients with this disease as it was based on postmortem tissues from patients at the extremes of metastatic failure (none to >100) encountered at autopsy. However, Winter et al used a similar approach based on a tissue microarray representing the survival extremes of resected patients which was nonetheless fruitful in identifying biomarkers of significance for this disease (4,10), as we now show for the p38-JNK pathway. Our approach also illustrates that biomarker studies of pancreatic cancer progression can be segregated into at least two categories: those that are consistently changed in expression with tumor progression (either gained or lost), and those that are heterogeneous in expression thereby highlighting subsets of pancreatic cancer with inherent differences in biology.
Research. 
The significance of p38 and JNK signaling in cancer is highly dependent on the cellular context and the tissue of origin (11,23). Moreover, while the significance of this pathway has been elucidated in several human tumor types, data are limited in pancreatic cancer as most studies have typically focused on mechanistic studies of only one or two cell lines and have shown opposite effects (12,13,34-36). Handra-Luca used immunolabeling for pp38 in resected pancreatic cancer tissues, although in that study pp38 overexpression was associated with a worse recurrence free survival (14-17,37).
Our findings now serve to clarify the role of p38 in pancreatic cancer by indicating it fulfills a tumor suppressive-type function through JNK inhibition, similar to that found in hematopoietic cells, fibroblasts and hepatocytes (18, 32) .
In a whole exome sequencing survey of 24 pancreatic cancers, Jones et al identified 12 core pathways that were recurrently targeted by somatic alteration in the majority of cancers analyzed, one of which was the JNK pathway (19, 20, 38) . Thus, our data based on protein expression in an independent set of pancreatic cancer tissues not only validate the relevance of this pathway, but also indicate that the significance of p38 expression may be for its effects on JNK. However, while the genetic alterations observed by Jones et al served to identify the JNK pathway, the functional consequences of these genes on JNK signaling were not defined. For example, short term activation of JNK may promote cell survival (21, 39) , whereas long term activation may lead to increased apoptosis such as through the E3 ubiquitin ligase ITCH that promotes c-Jun degradation (23, 40, 41) . Of interest, USP9x has recently been identified as a tumor suppressor in pancreatic cancer that also exerts it effects though regulation of ITCH expression (24, 42) , lending support to the notion that ITCH-dependent JNK signaling that leads to apoptosis, a consequence of chronic JNK activation by ongoing DNA damage (25, 43) , may be one of the cellular functions targeted.
Differential pp38 expression in pancreatic cancer may be due to underlying changes in expression of total p38, or to relative changes in activation (44) . However, most cases in the current study robustly expressed total p38 by immunolabeling analyses of tissue or Western blot analyses of cell line extracts, suggesting 
phosphorylation levels as the underlying mechanism of p38 activity. p38 may be activated by the canonical MAP2Ks MKK3 or MKK6, both of which are expressed in pancreatic cancer, or by MKK4 that also activates JNK (44) ; it may undergo autophosphorylation as well although this mechanism appears specific to activated Tlymphocytes (45) . However, p38 may also be dephosphorylated by a number of phosphatases thus providing an alternative mechanism for control of p38 activity and by extension JNK (44) . This possibility is perhaps most relevant given reports of frequent loss of DUSP6 and MKP1 expression in pancreatic cancer cells and tissues (46, 47) . Gli1 MMP9 GATA6   A33  A28  A11  A33  A92  A7  A7  A89  A93  A93  A5  A11  A65  A90  A90  A15  A15  A38  A38  A43  A2  A32  A32  A80  A80  A31  A31  A73  A73  A10  A3  A3  A85  A85  A87  A87  A17  A10  A17  A26  A26  A06  A88  A88  A06  A2  A52  A89  A42  A42  A29  A29  A55  A43  A53  A40  A28  A55  A61  A61  A77  A92  A22  A22  A95 
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